Zobrazeno 1 - 10
of 89
pro vyhledávání: '"Hepatitis C, Chronic/ drug therapy"'
Autor:
José Vera, André Gomes, Diana Póvoas, Diana Seixas, Fernando Maltez, Isabel Pedroto, Luís Maia, Margarida Mota, Maria João Vieira, Maria José Manata, Paula Ferreira, Sara Lino, Tiago Pereira Guedes, Vânia Barradas, Nuno Marques
Publikováno v:
Acta Médica Portuguesa (2024)
Introduction: Information about pan-genotypic treatments for hepatitis in Portugal is scarce. We aimed to evaluate the effectiveness and safety of glecaprevir plus pibrentasvir (GLE/PIB) treatment for hepatitis C virus (HCV) infection in real-world c
Externí odkaz:
https://doaj.org/article/c6949422f29c4c0cb3dfbb11673ce691
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Mediterranean Journal of Hematology and Infectious Diseases, Vol 9, Iss 1, Pp e2017019-e2017019 (2017)
Thrombocytopenia in patients with chronic hepatitis C virus (HCV) infection is a major problem. The pathophysiology is multifactorial, with auto-immunogenicity, direct bone marrow suppression, hypersplenism, decreased production of thrombopoietin and
Externí odkaz:
https://doaj.org/article/f2af53357c544c7e93c0ade328627792
Autor:
Cas J. Isfordink, Marleen van Dijk, Sylvia M. Brakenhoff, Patricia A.M. Kracht, Joop E. Arends, Robert J. de Knegt, Marc van der Valk, Joost P.H. Drenth, M. van den Berg, P. Honkoop, S. Abraham, S. Bosman, P. van Wijngaarden, K. Steenhuisen, P. Friederich, A.S. M. Dofferhoff, J. Berkhout, F. ter Borg, J.M. da Silva, M.A.M.T. Verhagen, X. Vos, K. Vlaar, R. Douma, W.G. Erkelen, M. den Reijer, C.J.P.A. Hoebe, J. Heil, M. Baven, H. van Soest, K. Sebib Korkmaz, G. Bezemer, A.J.J. Lammers, S.B. Debast, H.J.M. de Jong, P. Bus, P. Sturm, J. den Hollander, L.M. Kampschreur, N. Venneman, F. Bosma, O.M. Koc, R. Ackens, E. van Oorschot, M. Klemt-Kropp, L.C. Baak, J.T. Brouwer, B.W.M. Spanier, C. Swanink, H. Blokzijl, M. Knoester, P. Liedorp, J. van Bergeijk, A. van Nunen
Publikováno v:
European journal of internal medicine, 101, 93-97. Elsevier Science
European Journal of Internal Medicine, 101, pp. 93-97
European journal of internal medicine, 101, 93-97. Elsevier
European Journal of Internal Medicine, 101, 93-97. ELSEVIER SCIENCE BV
European Journal of Internal Medicine, 101, 93-97
European Journal of Internal Medicine, 101, 93-97. Elsevier
European Journal of Internal Medicine, 101, pp. 93-97
European journal of internal medicine, 101, 93-97. Elsevier
European Journal of Internal Medicine, 101, 93-97. ELSEVIER SCIENCE BV
European Journal of Internal Medicine, 101, 93-97
European Journal of Internal Medicine, 101, 93-97. Elsevier
Contains fulltext : 252163.pdf (Publisher’s version ) (Open Access) BACKGROUND & AIMS: The number of chronic hepatitis C virus (HCV)-infected patients who have been lost to follow-up (LTFU) is high and threatens HCV elimination. Micro-elimination f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8314930152d301bd4aed6c5cba90f1d8
https://cris.maastrichtuniversity.nl/en/publications/a01f1ffa-f2af-4cd1-a333-56362f481d9e
https://cris.maastrichtuniversity.nl/en/publications/a01f1ffa-f2af-4cd1-a333-56362f481d9e
Autor:
Ana Cláudia Miranda, Rosário Serrão, Josefina Mendez, Patrícia Pacheco, Sónia Rocha, Sara Pinto, Cristina Valente, Ana Paula Reis, André Gomes, Francisco Vale, Rosário Pazos, Rui Sarmento-Castro, Maria José Manata, Rui Pereira, Isabel Germano, Ana Martins
Publikováno v:
Journal of Viral Hepatitis
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Agência para a Sociedade do Conhecimento (UMIC)-FCT-Sociedade da Informação
instacron:RCAAP
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Agência para a Sociedade do Conhecimento (UMIC)-FCT-Sociedade da Informação
instacron:RCAAP
Direct-acting antiviral drugs (DAAs) have recently changed the paradigm of hepatitis C therapy, significantly improving treatment response rates, patient life expectancy and quality of life. In Portugal, sofosbuvir (SOF) and SOF/ledipasvir (SOF/LDV)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf72d778d4875c57ab343ccaf0dad349
http://europepmc.org/articles/PMC7317188
http://europepmc.org/articles/PMC7317188
Autor:
Smith, David A., Fernandez-Antunez, Carlota, Magri, Andrea, Bowden, Rory, Chaturvedi, Nimisha, Fellay, Jacques, McLauchlan, John, Foster, Graham R., Irving, William L., Simmonds, Peter, Pedergnana, Vincent, Ramirez, Santseharay, Bukh, Jens, Barnes, Eleanor, Ansari, M. Azim, Ball, Jonathan, Brainard, Diana, Burgess, Gary, Cooke, Graham, Dillon, John, Gore, Charles, Guha, Neil, Halford, Rachel, Herath, Cham, Holmes, Chris, Howe, Anita, Hudson, Emma, Irving, William, Khakoo, Salim, Klenerman, Paul, Koletzki, Diana, Martin, Natasha, Massetto, Benedetta, Mbisa, Tamyo, McHutchison, John, McKeating, Jane, Miners, Alec, Murray, Andrea, Shaw, Peter, Spencer, Chris C. A., Targett-Adams, Paul, Thomson, Emma, Vickerman, Peter, Zitzmann, Nicole
Publikováno v:
Nature Communications
Nature Communications, Vol 12, Iss 1, Pp 1-11 (2021)
STOP-HCV Consortium 2021, ' Viral genome wide association study identifies novel hepatitis C virus polymorphisms associated with sofosbuvir treatment failure ', Nature Communications, vol. 12, no. 1, 6105 . https://doi.org/10.1038/s41467-021-25649-6
Nature Communications, 2021, 12 (1), pp.6105. ⟨10.1038/s41467-021-25649-6⟩
Nature communications, vol. 12, no. 1, pp. 6105
Nature Communications, Vol 12, Iss 1, Pp 1-11 (2021)
STOP-HCV Consortium 2021, ' Viral genome wide association study identifies novel hepatitis C virus polymorphisms associated with sofosbuvir treatment failure ', Nature Communications, vol. 12, no. 1, 6105 . https://doi.org/10.1038/s41467-021-25649-6
Nature Communications, 2021, 12 (1), pp.6105. ⟨10.1038/s41467-021-25649-6⟩
Nature communications, vol. 12, no. 1, pp. 6105
Sofosbuvir is a common therapy in hepatitis C virus infection, which targets the NS5B polymerase. Here, Smith et al. analyze the association between whole genome HCV polymorphisms and sofosbuvir treatment failure and identify three common polymorphis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4c9cf99c929fe18ff1ccaeb9a812b730
Autor:
Anne Øvrehus, Peer Brehm Christensen, Lone Wulff Madsen, Martin Schou Pedersen, Ulrik Fahnøe, Jens Bukh
Publikováno v:
Wulff Madsen, L, Brehm Christensen, P, Fahnøe, U, Pedersen, M S, Bukh, J & Øvrehus, A 2021, ' Inferior cure rate in pilot study of 4-week glecaprevir/pibrentasvir treatment with or without ribavirin of chronic hepatitis C ', Liver International, vol. 41, no. 11, pp. 2601-2610 . https://doi.org/10.1111/liv.14991
Madsen, L W, Christensen, P B, Fahnøe, U, Pedersen, M S, Bukh, J & Øvrehus, A 2021, ' Inferior cure rate in pilot study of 4-week glecaprevir/pibrentasvir treatment with or without ribavirin of chronic hepatitis C ', Liver International, vol. 41, no. 11, pp. 2601-2610 . https://doi.org/10.1111/liv.14991
Madsen, L W, Christensen, P B, Fahnøe, U, Pedersen, M S, Bukh, J & Øvrehus, A 2021, ' Inferior cure rate in pilot study of 4-week glecaprevir/pibrentasvir treatment with or without ribavirin of chronic hepatitis C ', Liver International, vol. 41, no. 11, pp. 2601-2610 . https://doi.org/10.1111/liv.14991
Background & Aims: Shortening the treatment duration for chronic hepatitis C may increase feasibility and reduce the cost of cure. The aims of this study were to compare 4 weeks of glecaprevir/pibrentasvir (GLE/PIB) treatment with and without ribavir
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ed33771b24d3d7be32c1164eb6bccdd
https://portal.findresearcher.sdu.dk/da/publications/fd085708-411f-4356-a907-d9819192bf3f
https://portal.findresearcher.sdu.dk/da/publications/fd085708-411f-4356-a907-d9819192bf3f
Introdução: Estima-se que a infecção pelo vírus da hepatite C (VHC) acometa 3% da população global constituindo a maior causa de cirrose hepática e hepatocarcinoma. Nos pacientes infectados pelo genótipo 1 do VHC, a terapia em vida real com
Autor:
Marc Hazzan, Sébastien Dharancy, Christophe Legendre, Hélène Fontaine, Alain Duhamel, Nassim Kamar, Benjamin Legendre, Stanislas Pol, Corinne Antoine, Philippe Mathurin, Alexandre Louvet, Laurent Alric, Julien Labreuche
Publikováno v:
Journal of Hepatology
Journal of Hepatology, 2019, 70 (5), pp.831-838. ⟨10.1016/j.jhep.2018.12.036⟩
Journal of Hepatology, Elsevier, 2019, 70 (5), pp.831-838. ⟨10.1016/j.jhep.2018.12.036⟩
Journal of Hepatology, 2019, 70 (5), pp.831-838. ⟨10.1016/j.jhep.2018.12.036⟩
Journal of Hepatology, Elsevier, 2019, 70 (5), pp.831-838. ⟨10.1016/j.jhep.2018.12.036⟩
International audience; Background & aims: Before antiviral therapy, kidney transplant recipients infected with hepatitis B virus (HBV) or hepatitis C virus (HCV) had poor outcomes. Since the 90s, nucleos(t)ide analogues have been widely used in HBV-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4e4f9e412772509fd90466e2df10fb88
https://doi.org/10.1016/j.jhep.2018.12.036
https://doi.org/10.1016/j.jhep.2018.12.036
Publikováno v:
Viruses
Volume 14
Issue 8
Pages: 1613
Volume 14
Issue 8
Pages: 1613
In this study, we evaluated the effect of hepatitis C virus eradication using direct-acting antivirals (DAA) on the serum cytokine and growth factor profiles of chronic hepatitis C patients (CHC). Serum concentrations of 12 cytokines and 13 growth fa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d6080778a2c8771f8233575930d57be4
https://doi.org/10.3390/v14081613
https://doi.org/10.3390/v14081613